ArticleCurrent microbiology2026
Biological Activity of Polyquercetin Nanoparticles: A Potential Antimicrobial Agent.
Article in Current microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Viral and bacterial diseases are among the major health concerns despite improvements in drug development. Quercetin (QCT) and its derivatives have demonstrated significant antimicrobial activity. However, their structural limitations reduce their efficacy. This study aimed to synthesize and evaluate antiviral and antibacterial capacity of polyquercetin nanoparticles (PQCT NPs) in comparison with QCT. PQCT NPs were produced through oxidative self-polymerization of QCT, with manganese oxide nanosheets (MnO2) as oxidizing agent. The highly water-soluble PQCT NPs were characterized through TEM and SEM techniques. The antiviral potential was assessed against influenza A virus (IAV) H1N1/PR/8/34 in different combination treatments evaluating viral titer and cell viability using hemagglutination assay (HA) and MTT, respectively. Additionally, minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) of the compounds were determined by disk diffusion and Broth microdilution methods, respectively. PQCT NPs demonstrated significant antiviral activity against IAV as a viral infection model in all combination treatments. In pre-treatment the highest cellular protection (86.4%) along with 5.5 log reduction in viral titer (P < 0.01) were obtained. Co- and post-treatments also resulted in substantial viral titer reductions (6.5 and 4.5 log, respectively) and significant cellular protection compared to the virus control. In antibacterial assays, PQCT NPs exhibited strong activity against Gram-positive bacteria: Clostridium (C.) perfringenes, and Staphylococcus spp. including methicillin-resistant staphylococcus aureus (MRSA), with MIC values as low as 39.06 µg/mL. QCT showed minimal efficacies in both evaluations. These findings propose PQCT NPs as promising antiviral and antibacterial agent, particularly against IAV and Gram-positive bacteria, outperforming QCT in both efficacy and cellular protection.
Indexed as
Identifiers
42008000What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.